SH3BP5 and acute myeloid leukemia: In addition to age and cytogenetics risk, SH3BP5 expression was shown to be an independent prognostic factor for overall survival of AML patients (HR = 2.020, 95% CI:1.271–3.215, p = 0.0029) (Table 2).